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Abstract
Background: Though highly active antiretroviral therapy (HAART) has been available for more than a decade in
Ethiopia, information regarding mortality rates of human immunodeficiency virus (HIV)-positive children after
antiretroviral therapy antiretroviral therapy (ART) initiation is very scarce. Thus, this study intends to determine the
predictors of mortality among HIV-positive children receiving ART in Amhara Region.
Methods: A multicenter facility-based historical cohort study was conducted in 538 HIV-positive children on ART
from January 2012 to February 2017. We employed a standardized data extraction tool, adapted from ART entry
and follow-up forms. Descriptive analyses were summarized using the Kaplan-Meier survival curve and log rank test.
Then, the Cox-proportional hazard regression model was employed to estimate the hazard of death up to five-years
after ART initiation. Variables with p-values ≤0.25 in bivariable analysis were candidates to the multivariable analysis.
Finally, variables with p-values < 0.05 were considered as significant variables.
Results: The cohort contributed a total follow-up time of 14,600 child-months, with an overall mortality rate of 3.2
(95% CI: 2.3, 4.3) per 100 child-years. This study also indicated that HIV-infected children presenting with
opportunistic infections (OIs) (AHR: 2.5, 95% CI: 1.04, 5.9), anemia (AHR: 3.1, 95% CI: 1.4, 6.7), severe
immunodeficiency (AHR: 4.4, 95% CI: 1.7, 11.7), severe stunting (AHR: 3.3, 95% CI: 1.4, 8.0), severe wasting (AHR: 3.1,
95% CI: 1.3, 7.3), and advanced disease staging (III and IV) (AHR: 3.0, 95% CI: 1.2, 7.1) were at higher risk of mortality.
Conclusion: A higher rate of mortality was observed in our study as compared to previous Ethiopian studies. HIV-
positive children presenting with anemia, OIs, severe immunodeficiency, advanced disease staging (III and IV),
severe stunting, and severe wasting were at higher risk of mortality.
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Background
Human immunodeficiency virus (HIV) remains a serious
public health concern worldwide, but low and middle-
income countries (LMICs) are the most affected. In
2018, approximately 37.9 million people were living with
HIV worldwide, of whom 1.8 million were children
(age < 15 years) [1]. Sub-Saharan Africa (SSA) is a dis-
proportionally affected region contributing to approxi-
mately 91% of HIV-positive children in 2012 [2].
Globally, Acquired Immune Deficiency Syndrome
(AIDS) remains the leading cause of mortality among
children, resulting in 190,000 children deaths in 2013
[3]. In Ethiopia, 109,133 children are living with HIV
and approximately 2420 are newly infected with HIV an-
nually [4].
The use of anti-retroviral therapy (ART) has been ef-
fective in reducing mortality markedly among infected
children and adolescents [5]. In this regard, the World
Health Organization (WHO) exceeded its target of 15
million ART users by the end of 2015. Likewise, the
Ethiopian government launched cost-based ART in 2003
and cost-free ART in 2005, delivered as part of compre-
hensive HIV/AIDS care [6]. As a result, ART coverage
among children in Ethiopia has increased from 9% in
2013 to 58% in 2018 [7]. According to the recent Ethiop-
ian Demographic and Health Survey (EDHS, 2016), child
mortality in Ethiopia was reported as 67 per 1, 000 live
births. In our study area (Amhara Region), child mortal-
ity rate was reported as 85 per 1, 000 live births [8].
Despite different interventions undertaken by the
Ethiopian government, the mortality rate among HIV in-
fected children remains higher than the general pediatric
population. Previous studies done in Ethiopia reported
that the mortality rate in HIV-positive children receiving
ART ranged from 1.4 deaths per 100 child-years of ob-
servation [9] to 4 deaths per 100 child-years of observa-
tion [5]. These studies also reported that many factors
significantly increased the risk of mortality in this popu-
lation. For example, baseline anemia (Hgb < 10 g/dL) [5,
9], low CD4 count [5], advanced WHO clinical disease
staging (III & IV) [5, 9], poor ART drug adherence [10],
and malnutrition [11] were reported as factors signifi-
cantly increasing risk of mortality in HIV-positive chil-
dren receiving ART.
Obtusely, well-organized and up-to-date information
concerning mortality rate of HIV-positive children after
ART initiation is highly recommended to provide quality
care to HIV-positive children. However, although Am-
hara region has a particularly high child mortality rate, a
minimal number of studies have been conducted in this
area. Further, even though a few studies have been con-
ducted in Ethiopia, these studies have failed to consider
important predictors, such as malnutrition and develop-
mental status of the children, which significantly affect
the mortality rate of HIV-positive children [11, 12].
Thus, this study was conducted to address this know-
ledge and evidentiary gap by identifying the predictors of
mortality among HIV-positive children receiving ART in
Amhara Region referral hospitals, Northwest Ethiopia.
Methods
Study settings and period
This study was done in three purposely selected Amhara
Region Referral Hospitals between January 2012 and
February 2017. The three selected hospitals were Debre
Markos Referral Hospital, Felege Hiwot Comprehensive
Specialized Hospital, and University of Gondar Compre-
hensive Specialized Hospital, with respective locations of
299 km, 578 km, and 725 km from Addis Ababa, the cap-
ital city of Ethiopia. These hospitals were selected be-
cause they provide ART follow-up and care services for
a large proportion of HIV-positive patients in the region.
Together three hospitals provide inpatient and out-
patient services for more than 15 million people living in
the Amhara Region and neighboring regions. In addition
to other medical services, all the three hospitals provide
chronic HIV care (ART) for approximately 1071 chil-
dren in their catchment areas.
Study design and participants
A multicenter facility-based historical cohort study was
undertaken. All children living with HIV receiving ART
in all Amhara Region Referral Hospitals were our target
population. All randomly selected HIV-positive children
who took ART medication for a minimum of 1 month
during the follow-up period in the study hospitals were
included. Excluded participants were those with incom-
plete baseline variables.
Sample size and sampling technique
The minimum required sample size was estimated based
on the following variables: severe wasting, severe under-
weight, CD4 counts or percentage below the threshold,
anemia (Hgb < 10 g/dL), and WHO clinical stage III and
IV. However, the maximum calculated sample size was
obtained from CD4 cell count or percentage below the
threshold and was taken as our final sample size. Our
final sample size was calculated based on the following
parameters: P1: percent of exposed (CD4 count or %
below the threshold) with outcome (11.6%), P2: percent
among non-exposed (CD4 count or % above the thresh-
old) with outcome (4.4%), 95% CI, Zβ = 80% and r = 1: 1
ratio. The final sample size after adding a10% chart in-
completeness rate was 553. The parameters were taken
from a previous study conducted at Bahir Dar Referral
Hospital [5].
First, the medical charts of HIV-positive children
started on ART (740) prior to the follow-up period at
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the three selected hospitals were sorted. Next, 553 chil-
dren’s medical records were selected using a simple ran-
dom sampling technique. Lastly, data across 5 years
were extracted from each enrolled child’s record (Fig. 1).
Data extraction procedures
After reviewing some HIV-infected children charts
and similar articles, a standardized data extraction
checklist was carefully developed. The resulting data
extraction tool had the following components: socio-
demographic characteristics of caregivers and their
children and clinical characteristics and nutritional
status of the children. Trained data collectors care-
fully extracted all available data from the selected
medical records of HIV-positive children. The most
recent laboratory and clinical measurements docu-
mented at ART initiation were used as baseline
values. A daily base supervision was done by assigned
supervisors to maintain data quality. Besides, training
concerning data extraction process was given for both
data collectors and supervisors. Lastly, the consistency
between records and collected data was confirmed by
principal investigators through randomly selected re-
views of previously extracted medical records.
Measurements
The death of any HIV-positive child after ART initiation
during the five follow-up period was considered as an
event. Conversely, study participants who were still alive
at the end of follow-up, lost from the study, or
Footnote: proportion was calculated as follows: the total number of HIV-infected children on 
ART at a given hospital between January 1, 2012 and February 28, 2017 multiplied by our 
calculated sample size (553), then divided by the total number of HIV-infected children started 
ART in the three hospitals between January 1, 2012 and February 28, 2017 (740). 
For example, for DMRH, it was calculated as: 205*553/740=153.
Total number of children aged
<15 years) started ART at 
UOGCSH between January 1, 
2012 and February 28, 2017 
(N=275)
The selected three hospitals were: Debre Markos Referral Hospital (DMRH), Felege 
Hiwot Comprehensive Specialized Hospital (FHCSH), and University of Gondar 
Comprehensive Specialized Hospital (UOGCSH).
Total number of children
(aged <15 years) started ART 
at DMRH between January 1, 
2012 and February 28, 2017 
(N=205)
Total number of children aged
<15 years) started ART at 
FHCSH between January 1, 
2012 and February 28, 2017 
(N=260)
The final sample size was 553; however, after 
excluding 15 incomplete charts, 538 charts were 







The total number of children (aged< 15 years) started ART in the three 
hospitals between January 1, 2012 and February 28, 2017 (N=740)
Fig. 1 Schematic presentation of sampling procedure to assess the predictors among HIV-infected children on ART in Amhara Region Referral
Hospitals from January 1, 2012 to February 28, 2017. Footnote: proportion was calculated as follows: the total number of HIV-infected children on
ART at a given hospital between January 1, 2012 and February 28, 2017 multiplied by our calculated sample size (553), then divided by the total
number of HIV-infected children started ART in the three hospitals between January 1, 2012 and February 28, 2017 (740). For example, for DMRH,
it was calculated as: 205*553/740 = 153
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transferred to other health institutions were considered
as censored.
ART drug adherence level was calculated based on the
total monthly doses of ART. Good ART adherence was
documented when the compliance level was ≥95% or
missed doses were ≤ three per month. Fair ART adher-
ence was documented when the compliance level was
between 85 and 94% or missed doses were between four
and eight per month. Lastly, poor ART adherence was
documented when the compliance level was < 85% or
missed doses were ≥ nine per month [13].
HIV-positive children with weight for age (W/Age) Z-
score < − 2 SD, height for age (H/Age) Z-score < − 2 SD,
and weight for height (W/H) Z-score < − 2 SD were clas-
sified as moderately underweight, stunted, and wasted
respectively [14, 15].
HIV-positive children with W/Age Z-score < − 3 SD,
H/Age Z-score < − 3 SD, and W/H Z-score < − 3 SD
were classified as severely underweight, stunted, and
wasted respectively [14, 15].
The CD4 count below the threshold for ages < 12
months, 12–35 months, 36–59 months, and ≥ 5 years
were < 1500/mm3, < 750/mm3, < 350/mm3, and < 200/
mm3 respectively [16].
Data management and statistical analysis
Epi-Data™ Version 3.1 was used for data entry and
STATA™ Version 14 was used for statistical analysis. De-
scriptive statistics for continuous variables were summa-
rized using mean, median, and standard deviation. The
survival probability among HIV-infected children from
the date of ART initiation to event was estimated using
the Kaplan Meier survival curve. Cox proportional haz-
ard regression model was fitted, then all variables with
p-value ≤0.25 in the bivariable analysis were included in
a multivariable model. Cox-proportional hazard model
assumption was checked using Schoenfeld residual test
for continuous variables and Log-Log plots for categor-
ical variables. Besides, multicollinearity was checked
using the variance inflation factor (VIF). In the final
model, hazard ratios with 95% confidence intervals and
p-values (< 0.05) were used to identify statistically signifi-
cant predictors and measure the strength of association.
Results
Demographic characteristics of included participants
After reviewing 553 HIV-infected children’s records, 538
records were included in the final analysis as, 15 records
were excluded due to incompleteness. About half
(51.5%) of study participants were females and the ma-
jority of participants (83.6%) were from urban areas. The
baseline mean age of the participant cohort was 6.7 years
(SD: 3.8 years); with the mean age of caregivers reported
as 33.1 years (SD: 0.4 year). Details of another captured
socio-demographic characteristics are found in Table 1.
Baseline clinical, laboratory, and ART information
About 45.0% of the HIV-positive children had opportun-
istic infections (OIs) at ART initiation. Of these, 23.3,
20.9, and 17.1% of the children had diarrhea, pneumonia,
and tuberculosis, respectively (Fig. 2). About 57.6% of
the HIV-positive children had mild WHO clinical dis-
ease staging (stage I and II). Moreover, nearly two-thirds
(69.5%) of the children had CD4 counts below the
threshold. Furthermore, less than one-third (30.8%) of
the participants had anemia at ART initiation. Regarding
baseline nutritional status, 17.3, 22.7, and 16.7% of HIV-
infected children were severely underweight, stunted,
and wasted. Furthermore, about 12.3% of the children
were anemic during ART initiation (Table 2).
Table 1 Baseline demographic characteristics of HIV infected
children receiving ART in Amhara Region Referral Hospitals
between January 2012 and February 2017





< 1 year 22 4.1
1–4 years 169 31.4










Both alive 323 60
Father dead 94 17
Mother dead 48 9
Both dead 73 14
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Follow-up characteristics of the children
Throughout the follow-up time, 17.8% of the study
participants developed ART related side effects. Add-
itionally, nearly one-fourth (26.4%) of the children de-
veloped OIs during the follow-up time. Furthermore,
almost one-third (29.7%) of HIV-infected children had
a history of ART regimen change during the follow-
up time. Interestingly, about 4.7% of the children dis-
continued their medication during the follow-up time.
More than half (59.1%) of the HIV-positive children
were taking a combination of zidovudine, lamivudine,
and efavirenz or zidovudine, lamivudine, and nevira-
pine (Fig. 3).
Mortality rate during our follow-up
This cohort contributed a total follow-up time of 14,600
child-months. Among a cohort of 538 HIV-infected chil-
dren, 38 children (7.1%) died, 33 (6.1%) were lost to
follow-up, 81(15.1%) were transferred to other health in-
stitutions, and 386 (71.8%) remained in the follow-up.
Finally, the combined mortality rate of this cohort was
3.2 (95% CI: 2.3, 4.3) per 100 child-years of observation.
The number of deaths within the first three, six, and 12
months of ART follow-up were 19 (50%), 24 (63%), and
26 (68%), respectively. The 60months cumulative sur-
vival probability of HIV-infected children was 0.88 (95%
CI: 0.84, 0.92) (Fig. 4).
Predictors of mortality
In the final model, the following factors increased the
risk of mortality among HIV-positive children: baseline
OIs, anemia, severe immunodeficiency, advanced disease
stage, severe stunting, and severe wasting. We observed
that the hazard of death among children presenting with
OIs at ART initiation was 2.5 fold (AHR: 2.5, 95%CI:
1.04, 5.9) higher than to those presenting without OIs.
Additionally, the hazard of death among children who
initiated ART with severe disease was three-fold higher
as compared to those who initiated ART with mild dis-
ease (AHR: 3.0, 95% CI: 1.2, 7.1). Furthermore, the haz-
ard of death among children who had severe
immunodeficiency was 4.4 fold (AHR: 4.4, 95% CI: 1.7,
11.7) higher than to those who had mild immunodefi-
ciency. The hazard of death among anemic children was
three-fold (AHR: 3.1, 95% CI: 1.4, 6.7) higher as com-
pared to non-anemic children. Lastly, the hazard of
death among severely stunted, and severely wasted chil-
dren was three times higher as compared to their well-
nourished counterparts [(AHR: 3.3, 95% CI: 1.4, 8.0),
and (AHR: 3.1, 95% CI: 1.3, 7.3)] respectively (Table 3).
Discussion
This study identified the predictors of mortality among
HIV-positive children receiving ART using a multicenter
facility-based historical cohort study. Within a total
Fig. 2 Baseline opportunistic infections of HIV-infected children receiving ART in Amhara Region Referral Hospitals from January 1, 2012 to
February 28, 2017
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Table 2 Clinical, laboratory, and ART information of HIV infected children receiving ART in Amhara Region Referral Hospitals from
January 1, 2012 to February 28, 2017













Stage I and II 310 57.6
Stage III and IV 228 42.4
Past TB test before ART








CD4 count or percent
Severe immunodeficiency 374 69.5
Mild immunodeficiency 164 30.5
Hemoglobin level
Anemic(< 10 g/dl) 66 12.3
Non-anemic (≥10 g/dl) 472 87.7
ART eligibility criteria
Immunologic/ CD4 134 24.9
WHO clinical stage 67 12.5
Both clinical and immunologic 216 40.2




ART adherence in the 1st 3 months




Moderate (WAZ < - 2) 128 23.8
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follow-up time of 14,600 child-months, the mortality
rate of HIV-positive children receiving ART in our study
hospitals was 3.2 (95% CI: 2.3, 4.3) per 100 child-years of
observation. Our finding is comparable with studies re-
ported from Arba Minch Town Public Health Facilities,
Gamo Gofa Zone, Southern Ethiopia (3.1 deaths per 100
child-years) [17], Nigeria (3.0 deaths per 100 child-years)
[18], and Andhra Pradesh, India (3.0 deaths per 100
child-years) [19].
Nonetheless, our finding is lower than studies con-
ducted in Addis Ababa Public Hospitals, Ethiopia (12.4
deaths per 100 child-years) [20], Debre Tabor General
Hospital and Dessie Referral Hospital, Ethiopia (6.3
deaths per 100 child-years) [21], and Kenya (8.4 deaths
per 100 child-years) [22]. These significant disparities
across the reported studies could be due to the differ-
ences in sample size, study setting, follow-up period, and
clinical characteristics of the study participants. As an
example, the follow-up period for a study done at Debre
Tabor General Hospital and Dessie Referral Hospital
was 120months [21], whereas the follow-up period of
our study was 60 months. It is well understood that as
the follow-up period increases, the number of events
(death) also increases. Additionally, a study conducted in
Kenya included only 135 HIV-infected children [22];
however, our study included 538 HIV-infected children
Table 2 Clinical, laboratory, and ART information of HIV infected children receiving ART in Amhara Region Referral Hospitals from
January 1, 2012 to February 28, 2017 (Continued)
Variables Frequency (N) Percentage (%)
Severe (WAZ < −3) 93 17.3
Stunting (baseline)
Normal 336 62.5
Moderate (HAZ < −2) 80 14.9
Severe (HAZ < −3) 122 22.7
Wasting (baseline)
Normal 365 67.8
Moderate (WHZ or BAZ < −2) 83 15.4
Severe (WHZ or BAZ < − 3) 90 16.7
Fig. 3 Type of regimens during follow-up among HIV-infected children receiving ART in Amhara Region Referral Hospitals from January 1, 2012
to February 28, 2017
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with the smaller sample size potentially yielding a less
precise estimation.
This study also found a high rate of mortality when
compared to studies reported from Adama Referral Hos-
pital and Medical College, Ethiopia (2.1 deaths per 100
child-years) [23], Zambia (1.6 deaths per 100 child-
years) [24], and Malawi, Lesotho, and Swaziland (2.25
deaths per 100 child-years) [25]. The above variations
might be due to the differences in clinical characteristics
of the study participants and study settings as our study
included only referral hospitals. Additionally, our study’s
higher rate of mortality could be attributed to the clin-
ical characteristics of the included study participants
such as the nearly two-thirds (69.5%) of our study partic-
ipants having severe immunodeficiency.
Of 38 total deaths, 68% occurred within the first year
of ART initiation. This finding is comparable with a
study done at Bahir Dar Referral Hospital, Ethiopia,
found that the mortality rate within the first year after
ART commencement was 90.2% [5]. Moreover, this
finding is consistent with studies done in other SSA
countries, which documented that the death of most
HIV-positive children commonly happened in the early
phase of ART [26, 27]. Higher premature mortality in
our study might be associated with the clinical charac-
teristics of included participants as over two-thirds
(69.5%) of the study participants had CD4 counts below
the threshold, a population which usually experiences
higher early mortality after ART initiation. Moreover,
children with weakened immunity are more easily
attacked by different types of OIs, which are the most
common causes of premature death.
This study found that the risk of mortality among
anemic HIV-positive children was three-fold higher as
compared to their non-anemic counterparts. Previous
Ethiopian studies also documented that anemia had a
significant impact on the survival of HIV-infected chil-
dren [5, 9, 10, 12]. Additionally, studies reported from
other LMICs also reported that anemia at ART initiation
was significantly associated with higher mortality [22, 27,
28]. Furthermore, studies conducted elsewhere also
demonstrated that anemia is the most common
hematologic abnormality among people living with HIV.
It is significantly associated with low quality of life and a
higher risk of mortality [29, 30]. The most common
cause of anemia among people living with HIV is the
side effects of zidovudine, which 59.1% of our study par-
ticipants were taking a combination of Zidovudine, lami-
vudine, and efavirenz or Zidovudine, lamivudine, and
nevirapine. Cotrimoxazole preventive therapy (CPT), be-
ing reflected in 63.2% of our participants, can be an add-
itional cause of anemia among HIV-positive children.
This study also revealed that HIV-positive children
presenting with OIs at ART initiation were at higher
risk of mortality. A Tanzanian study also reported
that children who had TB and other OIs at ART ini-
tiation were at higher risk of mortality [28]. Besides, a
study from South Africa also demonstrated that OIs
in the form of chronic diarrhea was a significant pre-
dictor of mortality [26]. As OIs are the predominant
causes of morbidity and mortality among HIV-
infected patients, the Ethiopian National ART Guide-
lines strongly recommends treating OIs before ART
initiation [6]. In addition to the direct effect of these
OIs, patients may have died due to the side effects of
common drugs used to treat these OIs. Concerning
drug-drug interactions, studies suggested that HIV-
infected individuals treated with anti-TB medications
usually experience drug toxicity as compared to HIV-
uninfected individuals [31, 32]. As an example, a
study done in Canada revealed that HIV-infected
people treated with anti-TB medications were more
likely to develop drug-related adverse events [32].
Further finding of this current study demonstrated
that children who had severe immunodeficiency were at
higher risk of death as compared to those who had mild
immunodeficiency. This finding is in agreement with the
previous Ethiopian studies [5, 9, 12, 21]. Besides, a Bra-
zilian study also reported that baseline CD4 count below
15% significantly increased the hazard of death among
HIV-positive children [33]. Similarly, studies conducted
elsewhere have documented that HIV-positive children
with low CD4 count were at higher risk of mortality
than those who had high CD4 count [28, 34–36]. Gener-
ally, serious and life-threatening OIs, including CNS
toxoplasmosis and cryptococcal meningitis are frequent
Fig. 4 The overall Kaplan-Meier survival curve with 95% confidence
intervals of HIV-infected children receiving ART in Amhara Region
Referral Hospitals from January 1, 2012 to February 28, 2017
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among people having low CD4 count or percentages
which increases their vulnerability to death.
Another finding of this study revealed that the
death rate among children with advanced disease
stage (WHO stage III and IV) was higher as com-
pared to those children with mild disease stage
(WHO stage I and II). This finding is highly sup-
ported by previous studies conducted elsewhere [9,
10, 22, 23, 37, 38]. OIs are the most common mor-
bidities among HIV-positive children with advanced
WHO clinical disease stage, which indicates that the
risk of developing and recurrence of OIs increases as
the WHO clinical staging becomes more advanced.
Hence, people living with HIV commonly died due to
OIs rather than HIV/AIDS.
Finally, this study found that undernutrition in the
form severe stunting (H/Age Z-score < − 3 SD) and se-
vere wasting (W/H Z-score < − 3 SD) significantly in-
creased the risk of mortality among HIV-infected
children on ART. This finding is comparable with the
previous Ethiopian studies conducted elsewhere [11, 12].
Additionally, a Kenyan study also revealed that those
children who had baseline WHZ (Weight for Age Z-
score) < − 2 were at higher risk of death among HIV-
positive children receiving HAART [22]. Moreover, a
Tanzanian study also found that WHZ and BAZ (Body
Table 3 The bivariable and multivariable Cox regression analysis of predictors of mortality among HIV infected children receiving
ART in Amhara Region Referral Hospitals from January 1, 2012 to February 28, 2017
Variables Survival status CHR (95%CI) AHR (95%CI)
Dead Censored
Sex
Male 26 235 2.3 (1.2, 4.5) 1.4 (0.7, 2.9)
Female 12 265 1 1
Age
< 1 year 3 19 3.1 (0.9, 10.3) 2.8 (0.7, 10.7)
1–5 years 17 152 1.9 (1.0, 3.7) 1.6 (0.8, 3.5)
5–15 years 18 329 1 1
Residence
Urban 35 415 1 1
Rural 3 85 0.5 (0.2, 1.6) 0.5 (0.1, 1.6)
OI at baseline
Yes 30 212 4.6 (2.1, 10.0) 2.5 (1.04, 5.9)a
No 8 288 1 1
WHO clinical staging
Stage I and II 8 302 1 1
Stage III and IV 30 198 5.3 (2.4, 11.5) 3.0 (1.2, 7.1)a
CD4 count or percent
Severe immunodeficiency 33 341 3.0 (1.2, 7.7) 4.4 (1.7, 11.7)a
Mild immunodeficiency 5 159 1 1
Anemia
Anemic (< 10 g/dl) 15 51 5.4 (2.8, 10.4) 3.1 (1.4, 6.7)a
Non-anemic (≥10 g/dl) 23 449 1 1
Stunting
Normal 12 324 1 1
Moderate (HAZ < −2) 8 72 3.0 (1.2, 6.9) 2.0 (0.8, 5.3)
Severe (HAZ < −3) 18 104 4.6 (2.0, 9.5) 3.3 (1.4, 8.0)a
Wasting
Normal 18 347 1 1
Moderate (WHZ or BAZ < −2) 5 78 1.1 (0.4, 3.0) 1.3 (0.4, 3.7)
Severe (WHZ or BAZ < −3) 15 75 3.2 (1.6, 6.5) 3.1 (1.3, 7.3)a
a Significant predictors in the multivariable analysis
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Mass Index for Age Z-score) of ≤ -2 significantly associ-
ated with higher risk mortality within the first 3 months
of ART initiation [28]. Generally, the causes of undernu-
trition among HIV-patients are multidimensional and
multifactorial. HIV decreases food consumption as a re-
sult of swallowing difficulty caused by oral trash or
esophageal candidiasis, reduces nutritional absorption
caused by gastrointestinal mucosal damage, and in-
creases the metabolic demands [39, 40].
Limitations of the study
The major limitation of this study was the lack of quality
data to verify death status, especially for those who died
at home. This gap does not only affect the loss to
follow-up, but also may be an under-reporting of out-
comes of community-based individuals. In addition, this
study did not incorporate important predictors, like viral
load and micronutrient deficiency due to incomplete re-
cording system. Finally, early mortality could be under-
estimated since the study excluded children’s who had
ART follow-up was less than 1 month.
Conclusions
A higher rate of mortality was observed in our study as
compared to previous Ethiopian studies. Anemia, OIs,
low CD4 counts or percentages, advanced disease sta-
ging (III and IV), severe stunting, and severe wasting
were factors found as significantly increasing the risk of
mortality among HIV-infected children receiving ART.
Therefore, clinicians should emphasize early screening,
managing OIs, and maximizing nutritional supplements
for HIV infected children to improve the survival rate of
those individuals. Additionally, clinicians should give
more emphasis to malnourishment in HIV-infected chil-
dren at ART initiation. Furthermore, greater attention
and close follow-up shall be given for HIV-infected chil-
dren in the early ART phase.
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